د. علياء اسماعيل، أ.د. سالم اسماعيل و أ.د. ندى العلوان

WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Vol. 6 Issue 6, 2017

ABSTRACT
Background: Breast cancer is the most common malignant tumor in women worldwide and in Iraq. Many studies show BRCA1 and zinc are the substances that expressed significantly in tissues or serum specimens from a genetically–inherited cancer compared with a sporadic cancer or to healthy individuals, which in turn should be considered as a biological markers. Objectives: To describe serum BRCA1 and zinc levels as a novel biomarkers and correlating between them within familial patients comparing with sporadic breast cancer beside healthy controls group. Patients and Methods: 64 BC patients and 25 HCs. The patients were subjected after mastectomy age ranged (28-68 years) at the time of diagnosis. Serum BRCA1-ELISA method and serum zinc were performed. Results: The three groups were: familial breast cancer FBC 37 (41.6%) age mean 44.78 ± 10.3, sporadic SBC 27(30.3%) age mean 47.85 ± 9.8 and healthy controls HCs 25 (28.1%) age mean 44.00 ± 10.7. The median serum BRCA1 was significantly correlated with breast cancers compared with healthy controls and correlated more precisely with familial compared with sporadic breast cancer, while mean serum zinc was inversely correlated with breast cancer patients compared with healthy controls. Serum BRCA1 had a significant an indirect linear correlation with serum zinc. Conclusions: Serum BRCA1 and zinc can be used as a tests in the early detection, diagnosis, prognosis and therapy responses as a novel biomarkers of breast cancer in Iraqi women, moreover, serum BRCA1 can be used as a test to discriminate familial from sporadic breast cancer.

KEYWORDS: Breast, Cancer, Serum BRCA1, Serum zinc, familial breast cancer

Comments are disabled.